Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins

Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins

Item

http://www.wikidata.org/entity/Q34343774

Q34343774

about

Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdk2 and cdk4 Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors Therapeutic targets for HIV-1 infection in the host proteome.Use of a multi-virus array for the study of human viral and retroviral pathogens: gene expression studies and ChIP-chip analysis Roscovitine in cancer and other diseases Current and potential treatments for ubiquitous but neglected herpesvirus infections Antiviral activity of CYC202 in HIV-1-infected cells Novel agents and strategies to treat herpes simplex virus infections.p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.Site-specific regulation of histone H1 phosphorylation in pluripotent cell differentiation Inhibition of human immunodeficiency virus type-1 by cdk inhibitors Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus.CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses.Accumulation of substrates of the anaphase-promoting complex (APC) during human cytomegalovirus infection is associated with the phosphorylation of Cdh1 and the dissociation and relocalization of APC subunits.Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7.ViralPhos: incorporating a recursively statistical method to predict phosphorylation sites on virus proteins.Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.Phosphorylation of the VP16 transcriptional activator protein during herpes simplex virus infection and mutational analysis of putative phosphorylation sites.Development of new antivirals for herpesviruses.Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex Identifying protein phosphorylation sites with kinase substrate specificity on human viruses.Cdk inhibitory nucleoside analogs prevent transcription from viral genomes.Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1 Geldanamycin, a ligand of heat shock protein 90, inhibits the replication of herpes simplex virus type 1 in vitro.Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.The differential requirement for cyclin-dependent kinase activities distinguishes two functions of herpes simplex virus type 1 ICP0.Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication Novel HIV-1 therapeutics through targeting altered host cell pathways.Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production.Phosphorylation site mutations affect herpes simplex virus type 1 ICP0 function.Viral serine/threonine protein kinases Potential of protein kinase inhibitors for treating herpesvirus-associated disease.Design and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach.Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells.Herpes simplex virus-type 2 infectivity and agents that block gap junctional intercellular communication.Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity.Varicella-zoster virus IE63 protein phosphorylation by roscovitine-sensitive cyclin-dependent kinases modulates its cellular localization and activity.Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus.

P2860

Q24537780-9E21847B-3D95-4661-9EF9-9C462C5D5FDB Q24562983-8B64ED60-D71A-4AC2-86C0-0135045C0E9B Q24795470-0A325EBD-FC4F-4954-BADD-6CE9C2F6D457 Q24799552-03EB19F9-6D68-445F-94C6-DFB6B40F89AC Q26799874-63EE7EFE-DB64-45C1-8D83-8DC28C8CFA99 Q27023452-B2F8D86C-996F-4AB2-86DC-A564C22850D6 Q28292152-F74DD3F4-81A8-48D0-86C4-DACDC1CCFB1A Q30332444-683FAA56-5F85-49D2-805E-0C22283F0BCF Q30847612-8FB1C365-B7A5-40CC-BCA9-EE4E91EB6124 Q33716938-0DEED425-128B-423D-916A-24AF894AFC49 Q33780297-6E835277-3193-413B-A77B-1090F1A41FB3 Q33793543-A6A6D05A-3927-46C0-9966-8C1E3F1DEE2B Q33944230-C60C5877-1BD9-4D0C-815B-828FE963986A Q34007645-1C13E961-615B-476F-8CC0-D0E7FA7A2333 Q34228694-2FA5BC5D-2782-4884-94AF-01B9AFCD499A Q34406358-65A1BC30-6982-4ED1-AE5D-CED86B892947 Q34553293-AD8DE066-E960-4C1A-8A30-56E3766E3634 Q35106892-F879AE8A-2BA9-4F1D-9042-1A9F9FB31744 Q35253876-1816A600-4907-4111-96DC-A19FF081892A Q35669533-C0E47B6B-7B28-4984-A9FF-51B42FC5966E Q35940053-09EFC350-2BAA-4C50-BD5E-0493B37E4798 Q36109734-21342697-591B-478B-B83D-EE6D46C078A0 Q36296415-14B9CCEC-330E-48C4-986E-D442A3642ED4 Q36455362-ECB08F1C-3187-45EB-9317-8C63E8073D7D Q36491843-5638E3B3-3F99-4808-95B4-1C306E3DC744 Q36709312-9DDFCECA-B55E-4976-AD99-E344139C0CF2 Q36716750-192E2BBD-B044-4017-96B1-C1991A9D81EF Q37060135-1C54CA31-CB48-463A-9BF1-797A2F2392BF Q37368099-14E46FD8-90B4-4690-84AF-121304440644 Q37445903-5AE631B6-628C-4095-9EF2-7B226E0C216E Q37567845-93A095AE-B874-4AA0-AD7F-E67718C2545B Q37743081-9B309723-82EB-4F23-BF24-F0F14776595C Q37810382-A7D0C4C4-ACAE-4E69-8606-7EE66E4D23DD Q38100859-D27973AB-E99E-4128-90F7-28276D811443 Q38227257-F1223220-62C7-46FA-842A-D0313DE9BD31 Q39410825-1E6F28DC-B133-4BA0-8289-F8279C085AD7 Q40198778-D881C0F7-77E1-4D28-8094-A8811E6886ED Q40280118-4245F83C-98CF-4F4E-A93F-D849F344BA5D Q40409988-ED1628F9-DE09-4814-A061-DB6CB81F5C3A Q40584589-B9B451D4-CEFB-42AA-B66F-A9DF019E4C17

P2860

Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins

Item

http://www.wikidata.org/entity/Q34343774

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu